The Floyd A. Fried Advances in Urology Symposium
The Floyd A. Fried Advances in Urology Symposium will be held at the Rizzo Center on June 23rd and 24th, 2023.
This program is targeted for Urologists, Medical Oncologists, Radiation Oncologists, Internal, Family, Geriatric Practitioners, Physician Extenders, Nurses, Radiation Technicians, and other allied medical staff
Samir Taneja, MD
A few years later, I learned about an early acceptance program offered by Northwestern University’s Feinberg School of Medicine. I was accepted into the program in my senior year of high school and entered medical school after two years of college. I initially pursued neurosurgery, but a friend recommended urology. I liked the people in the field and was fascinated by the interaction of hormones and cancer within the prostate. I was fortunate to be allowed to conduct independent research in the department’s famous prostate cancer research laboratories and to have a world-renowned surgeon as my mentor, and so the course of my career as a surgeon in prostate cancer care and research was set.
When I first joined NYU Langone I focused broadly on urologic oncology, treating people with cancers of the prostate, kidney, bladder, and testis. Now, about 70 percent of my practice focuses on prostate cancer or the suspicion of prostate cancer.
The work I have been able to conduct at NYU Langone and its Perlmutter Cancer Center and Smilow Comprehensive Prostate Cancer Center has transformed the field of prostate cancer diagnosis and treatment by improving methods of prostate imaging, cancer detection, and disease localization. I strive to integrate new technologies into my practice to evolve the practice of oncology. This has allowed me to care for prostate cancer patients individually by avoiding surgery or radiation when not needed, and using new targeted approaches to treat the disease when possible. When conventional surgery is necessary, more than 90 percent of the surgical procedures I now perform are done laparoscopically with robotic assistance. This allows my patients to avoid large, open incisions, experience less pain and discomfort, and recover more quickly.
My clinical research focuses on the use of imaging to detect and treat prostate cancer. I pioneered the use of MRI to diagnose and pinpoint prostate cancer, and in MRI-guided focal ablative therapies that aim to destroy only the cancerous portion of the prostate. With the ability to precisely locate the cancer, patients no longer need to have the entire gland removed. Through ongoing improvements in imaging and constant integration of new technologies, we continue to evolve this approach to minimize the trauma of prostate cancer surgery.
I have authored more than 200 articles, 30 book chapters, and 6 textbooks and monographs on urologic cancer and surgery. In addition, I am the editor of Taneja’s Complications of Urologic Surgery: Prevention and Diagnosis, one of the most widely read textbooks in American urology.
Caroline Moore, MD
Professor of Urology
University College London
After completing her early medical training in London, she gained membership of the Royal College of Surgeons, who subsequently awarded her a research fellowship. Her research began in 2002 on evaluating photodynamic therapy for prostate cancer. It became the subject of her MD, which was completed in 2007, and led to the first completed randomised trial comparing focal treatment for prostate cancer with active surveillance. Later, she published the first study using magnetic resonance imaging (MRI) to evaluate treatment in early prostate cancer.
Moore started using MRI to detect prostate cancer in men who would not need treatment, and found that if biopsies were performed before MRI scans the images were blurred.
In October 2012 she established a committee on Standards in Reporting in MRI-targeted biopsy. The recommendations included reporting histologic results of standard cores using Gleason scores and maximum core cancer length, as well as reporting the recruitment criteria, radiologist experience and population biopsy status of a particular trial. She has worked on a combination of multi-parametric MRI and cognitive fusion transperineal biopsy, which can reduce the time taken diagnose and treat diseases. She has found that using MRI can reduce the need for biopsies by 28%. In 2019, her MRI protocols were approved by the National Institute for Health and Care Excellence (NICE), and incorporated into national guidance for the investigation of men suspected of having clinically localised prostate cancer.
Moore has developed electronic psychometric patient-reported outcome measures to monitor men who have had radical prostatectomy. Men who have this surgery can suffer from urinary leakage and difficulties with erections. The survey allows researchers to track their progress and share information with their surgical teams. Moore has been among a group of researchers spread across six hospitals who have been investigating high-intensity focused ultrasound (HIFU) as a treatment for prostate cancer. Five years after treatment with HIFU the cancer survival rate is 100%, the same as for the more traditional methods of surgery and radiotherapy, but with fewer side-effects.
She has been Head of Urology at University College London, within the Division of Surgical and Interventional Sciences since 2018. She was senior author on the Prostate Evaluation for Clinically Important Disease: Sampling Using Image Guidance or Not? (PRECISION) study comparing standard prostate biopsy and MRI-targeted biopsy.
In 2019 Moore was the first woman in the United Kingdom to be made a Professor of Urology. Her research has been supported by Prostate Cancer UK, the Movember Foundation, the Cancer Vaccine Institute, the National Institute for Health Research, the European Association of Urology Research Foundation, the Wellcome Trust and the Department of Health.